Kilambi News
Tuesday, November 17, 2026

FDA rejects Summit and Akeso lung cancer drug ivonescimab

Life Sciences Sunday, November 15, 2026 - Updated Nov 15, 2026 10:42

The FDA has issued a complete response letter declining to approve Summit Therapeutics and Akeso's ivonescimab with chemotherapy for previously treated EGFR mutated lung cancer, saying the application lacks a statistically significant survival benefit.

Why it matters: The decision resolves the pending FDA watch flagged in this morning's edition and blocks the first US approval of a PD-1 x VEGF bispecific antibody, a drug class Summit is still testing in several other Phase III trials.

Data as of Summit Therapeutics announcement of November 15, 2026, read in full (Business Wire release syndicated copy), with STAT and Reuters reports of the same day. The FDA's complete response letter itself is not public; its reasoning is as stated in Summit's release. Developing item.

The Food and Drug Administration has issued a complete response letter for ivonescimab, Summit Therapeutics said on Sunday, meaning the biologics licence application cannot be approved in its present form. The application covered ivonescimab, a PD-1 x VEGF bispecific antibody developed with China’s Akeso, combined with platinum chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer who had already received an EGFR targeted therapy.

The FDA determined that substantial evidence of effectiveness is not established without a statistically significant overall survival improvement, and that the progression free survival benefit seen in the Phase III HARMONi trial does not on its own support a positive benefit risk profile, according to Summit. HARMONi met its progression endpoint, and Summit said a longer follow-up analysis showed a survival hazard ratio of 0.76 across the full population, but the primary survival analysis did not reach statistical significance. Summit said it will continue ivonescimab’s wider development programme, including first line lung cancer trials, and noted that no regimen has shown a statistically significant survival benefit in this treatment setting.

Sources

  1. Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application - Summit Therapeutics, via Business Wire - 2026-11-15
  2. FDA rejects ivonescimab, lung cancer treatment from Summit Therapeutics - STAT - 2026-11-15
  3. US FDA declines to approve Summit lung cancer drug after trial misses key survival goal - Reuters - 2026-11-15